$LAB
STANDARD BIOTOOLS INC.

2023 Q3 Form 10-Q Financial Statement

#000162828023028287 Filed on August 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2
Revenue $25.37M $27.67M $18.78M
YoY Change -1.09% 47.34% -39.46%
Cost Of Revenue $14.21M $14.06M $14.35M
YoY Change -13.47% -1.99% -1.69%
Gross Profit $11.15M $13.60M $4.427M
YoY Change 20.98% 207.25% -73.04%
Gross Profit Margin 43.97% 49.17% 23.58%
Selling, General & Admin $22.29M $22.60M $30.38M
YoY Change -24.68% -25.62% 25.31%
% of Gross Profit 199.86% 166.15% 686.33%
Research & Development $6.370M $6.184M $12.61M
YoY Change -26.36% -50.94% 33.52%
% of Gross Profit 57.11% 45.46% 284.75%
Depreciation & Amortization $3.980M $3.626M $3.835M
YoY Change 10.49% -5.45% -1.64%
% of Gross Profit 35.68% 26.66% 86.63%
Operating Expenses $32.33M $31.05M $42.99M
YoY Change -40.87% -27.77% -10.97%
Operating Profit -$21.17M -$17.45M -$38.56M
YoY Change -27.06% -54.75% 123.32%
Interest Expense $1.223M $1.129M -$23.35M
YoY Change 16.59% -104.83% -2706.14%
% of Operating Profit
Other Income/Expense, Net $1.448M $1.839M -$3.238M
YoY Change -770.37% -156.79% -742.46%
Pretax Income -$20.95M -$16.74M -$65.15M
YoY Change -30.5% -74.31% 268.92%
Income Tax $100.0K $300.0K -$1.613M
% Of Pretax Income
Net Earnings -$21.00M -$17.04M -$63.54M
YoY Change -28.64% -73.18% 270.64%
Net Earnings / Revenue -82.77% -61.59% -338.39%
Basic Earnings Per Share -$0.27 -$0.22 -$0.82
Diluted Earnings Per Share -$0.27 -$0.22 -$816.5K
COMMON SHARES
Basic Shares Outstanding 78.96M shares 78.38M shares 77.25M shares
Diluted Shares Outstanding 79.15M 78.67M shares 77.82M shares

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $128.9M $142.3M $211.2M
YoY Change -30.41% -32.62% 584.35%
Cash & Equivalents $79.66M $142.3M $74.36M
Short-Term Investments $49.20M $0.00 $136.9M
Other Short-Term Assets $3.400M $3.567M $5.938M
YoY Change -26.23% -39.93% -10.07%
Inventory $21.93M $22.08M $22.79M
Prepaid Expenses
Receivables $16.56M $15.12M $10.94M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $170.7M $183.1M $250.9M
YoY Change -25.45% -27.03% 220.79%
LONG-TERM ASSETS
Property, Plant & Equipment $24.54M $24.52M $62.69M
YoY Change -7.7% -60.88% 126.16%
Goodwill $106.2M $106.3M
YoY Change 0.15%
Intangibles $4.200M $7.000M
YoY Change -72.73%
Long-Term Investments
YoY Change
Other Assets $2.390M $2.754M $2.241M
YoY Change -23.37% 22.89% -45.42%
Total Long-Term Assets $168.5M $172.8M $190.2M
YoY Change -9.34% -9.19% -9.88%
TOTAL ASSETS
Total Short-Term Assets $170.7M $183.1M $250.9M
Total Long-Term Assets $168.5M $172.8M $190.2M
Total Assets $339.3M $355.8M $441.1M
YoY Change -18.23% -19.34% 52.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.327M $6.089M $9.016M
YoY Change -21.26% -32.46% -19.67%
Accrued Expenses $10.20M $7.176M $18.62M
YoY Change 47.51% -61.45% 114.42%
Deferred Revenue $11.23M $11.69M
YoY Change -0.78%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.000M $4.583M $0.00
YoY Change 500.24%
Total Short-Term Liabilities $51.80M $46.84M $42.77M
YoY Change 12.2% 9.52% -19.07%
LONG-TERM LIABILITIES
Long-Term Debt $59.60M $60.66M $64.55M
YoY Change -6.71% -6.02% 19.66%
Other Long-Term Liabilities $1.086M $843.0K $58.36M
YoY Change -7.26% -98.56% 21043.48%
Total Long-Term Liabilities $1.086M $843.0K $122.9M
YoY Change -7.26% -99.31% 44429.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $51.80M $46.84M $42.77M
Total Long-Term Liabilities $1.086M $843.0K $122.9M
Total Liabilities $159.8M $158.0M $167.3M
YoY Change -4.0% -5.6% -6.97%
SHAREHOLDERS EQUITY
Retained Earnings -$981.0M -$960.0M
YoY Change 8.37%
Common Stock $82.00K $81.00K
YoY Change 3.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$131.7M -$113.4M $273.8M
YoY Change
Total Liabilities & Shareholders Equity $339.3M $355.8M $441.1M
YoY Change -18.23% -19.34% 52.47%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2
OPERATING ACTIVITIES
Net Income -$21.00M -$17.04M -$63.54M
YoY Change -28.64% -73.18% 270.64%
Depreciation, Depletion And Amortization $3.980M $3.626M $3.835M
YoY Change 10.49% -5.45% -1.64%
Cash From Operating Activities -$11.42M -$9.329M -$29.99M
YoY Change -53.6% -68.89% 104.5%
INVESTING ACTIVITIES
Capital Expenditures $900.0K $838.0K -$938.0K
YoY Change -171.2% -189.34% -77.52%
Acquisitions
YoY Change
Other Investing Activities -$49.02M $40.96M -$137.3M
YoY Change -508.5% -129.83%
Cash From Investing Activities -$49.93M $40.13M -$138.2M
YoY Change -565.07% -129.03% 3213.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.170M -2.084M 213.0M
YoY Change 23300.0% -100.98% -160218.8%
NET CHANGE
Cash From Operating Activities -11.42M -9.329M -29.99M
Cash From Investing Activities -49.93M 40.13M -138.2M
Cash From Financing Activities -1.170M -2.084M 213.0M
Net Change In Cash -62.52M 28.71M 44.73M
YoY Change 350.43% -35.81% -335.81%
FREE CASH FLOW
Cash From Operating Activities -$11.42M -$9.329M -$29.99M
Capital Expenditures $900.0K $838.0K -$938.0K
Free Cash Flow -$12.32M -$10.17M -$29.05M
YoY Change -47.23% -65.0% 176.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001162194
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P6M
CY2023Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2023Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2023Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Registrant Name
EntityRegistrantName
STANDARD BIOTOOLS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0513190
dei Entity Address Address Line1
EntityAddressAddressLine1
2 Tower Place
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 2000
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
266-6000
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
LAB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
78964770 shares
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142304000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81309000 usd
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
84475000 usd
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
331000 usd
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
592000 usd
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
15119000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
17280000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
22080000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
21473000 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3567000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4278000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
183070000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
208815000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24522000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25652000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
32194000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
33883000 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2754000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3109000 usd
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7000000 usd
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
12600000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
106287000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
106251000 usd
CY2023Q2 us-gaap Assets
Assets
355827000 usd
CY2022Q4 us-gaap Assets
Assets
390310000 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
6089000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7914000 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9765000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9153000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3912000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3682000 usd
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11685000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10792000 usd
CY2023Q2 lab Deferred Grant Revenue Current
DeferredGrantRevenueCurrent
3630000 usd
CY2022Q4 lab Deferred Grant Revenue Current
DeferredGrantRevenueCurrent
3644000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7176000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6175000 usd
CY2023Q2 us-gaap Secured Debt Current
SecuredDebtCurrent
4583000 usd
CY2022Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
2083000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
46840000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
43443000 usd
CY2023Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
54853000 usd
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
54615000 usd
CY2023Q2 us-gaap Secured Long Term Debt
SecuredLongTermDebt
5809000 usd
CY2022Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
8194000 usd
CY2023Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1049000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
1055000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
32231000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34081000 usd
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3790000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
3816000 usd
CY2023Q2 lab Deferred Grant Revenue Noncurrent
DeferredGrantRevenueNoncurrent
12546000 usd
CY2022Q4 lab Deferred Grant Revenue Noncurrent
DeferredGrantRevenueNoncurrent
14359000 usd
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
843000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
961000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
157961000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
160524000 usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
256000 shares
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
256000 shares
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
256000 shares
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
256000 shares
CY2023Q2 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
256000 shares
CY2023Q2 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
256000 shares
CY2023Q2 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
255559000 usd
CY2022Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
255559000 usd
CY2023Q2 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
311253000 usd
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
311253000 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9744000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
9744000 shares
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
82002000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
79904000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79121000 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79482000 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
81000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
80000 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
853466000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
847008000 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1551000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1896000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-959979000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-926096000 usd
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
2881000 shares
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
422000 shares
CY2023Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
5404000 usd
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
563000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-113387000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-81467000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
355827000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
390310000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27666000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18777000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52785000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45281000 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14064000 usd
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14350000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
26846000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
28617000 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
13602000 usd
CY2022Q2 us-gaap Gross Profit
GrossProfit
4427000 usd
us-gaap Gross Profit
GrossProfit
25939000 usd
us-gaap Gross Profit
GrossProfit
16664000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6184000 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12606000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12669000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21471000 usd
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22600000 usd
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30084000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
43895000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
59569000 usd
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
2267000 usd
CY2022Q2 us-gaap Restructuring Charges
RestructuringCharges
300000 usd
us-gaap Restructuring Charges
RestructuringCharges
3417000 usd
us-gaap Restructuring Charges
RestructuringCharges
1690000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
31051000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
42990000 usd
us-gaap Operating Expenses
OperatingExpenses
59981000 usd
us-gaap Operating Expenses
OperatingExpenses
82730000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17449000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-38563000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-34042000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-66066000 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
1129000 usd
CY2022Q2 us-gaap Interest Expense
InterestExpense
1062000 usd
us-gaap Interest Expense
InterestExpense
2246000 usd
us-gaap Interest Expense
InterestExpense
2092000 usd
CY2023Q2 lab Loss On Forward Sale Of Stock
LossOnForwardSaleOfStock
0 usd
CY2022Q2 lab Loss On Forward Sale Of Stock
LossOnForwardSaleOfStock
22289000 usd
lab Loss On Forward Sale Of Stock
LossOnForwardSaleOfStock
0 usd
lab Loss On Forward Sale Of Stock
LossOnForwardSaleOfStock
60081000 usd
CY2023Q2 us-gaap Debt Securities Gain Loss
DebtSecuritiesGainLoss
0 usd
CY2022Q2 us-gaap Debt Securities Gain Loss
DebtSecuritiesGainLoss
-3064000 usd
us-gaap Debt Securities Gain Loss
DebtSecuritiesGainLoss
0 usd
us-gaap Debt Securities Gain Loss
DebtSecuritiesGainLoss
-13719000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1839000 usd
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-174000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2969000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-56000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16739000 usd
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-65152000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33319000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-142014000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
301000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1613000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
564000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2187000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17040000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-63539000 usd
us-gaap Net Income Loss
NetIncomeLoss
-33883000 usd
us-gaap Net Income Loss
NetIncomeLoss
-139827000 usd
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.82
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.82
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.81
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.81
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78669000 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78669000 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77821000 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77821000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78873000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78873000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77430000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77430000 shares
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17040000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-63539000 usd
us-gaap Net Income Loss
NetIncomeLoss
-33883000 usd
us-gaap Net Income Loss
NetIncomeLoss
-139827000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-327000 usd
CY2022Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-485000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-157000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-635000 usd
CY2023Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
104000 usd
CY2022Q2 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-711000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
502000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-711000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-223000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1196000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
345000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1346000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17263000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64735000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33538000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-141173000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-81467000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-93000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3148000 usd
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2466000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-16843000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
568000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-97153000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-36000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
326000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3114000 usd
CY2023Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2375000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-17040000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-223000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-113387000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
94596000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-89000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4042000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-76288000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-150000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
22113000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-88000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
497000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
96000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4663000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-63539000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-1196000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-37454000 usd
us-gaap Net Income Loss
NetIncomeLoss
-33883000 usd
us-gaap Net Income Loss
NetIncomeLoss
-139827000 usd
lab Loss On Forward Sale Of Stock
LossOnForwardSaleOfStock
0 usd
lab Loss On Forward Sale Of Stock
LossOnForwardSaleOfStock
60081000 usd
us-gaap Debt Securities Gain Loss
DebtSecuritiesGainLoss
0 usd
us-gaap Debt Securities Gain Loss
DebtSecuritiesGainLoss
-13719000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6262000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
8705000 usd
lab Amortization Of Developed Technology Rights
AmortizationOfDevelopedTechnologyRights
5600000 usd
lab Amortization Of Developed Technology Rights
AmortizationOfDevelopedTechnologyRights
5928000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
1688000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
1878000 usd
us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
572000 usd
us-gaap Inventory Lifo Reserve Period Charge
InventoryLIFOReservePeriodCharge
4597000 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
3526000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
410000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
423000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
-168000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
176000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2238000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-7277000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1939000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6484000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-426000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1304000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1774000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1712000 usd
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
659000 usd
us-gaap Increase Decrease In Deferred Compensation
IncreaseDecreaseInDeferredCompensation
3598000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
937000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1557000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1158000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-4602000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17814000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45578000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
6836000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
137302000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
91964000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Other Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfOtherInvestments
0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1848000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1806000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
83280000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-139108000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
25000000 usd
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0 usd
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
225000000 usd
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
0 usd
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
6838000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
12547000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
4841000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
326000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
497000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
127000 usd
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
79000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4642000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
231033000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-49000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-437000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
60775000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
45910000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82324000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29467000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143099000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75377000 usd
us-gaap Interest Paid Net
InterestPaidNet
1919000 usd
us-gaap Interest Paid Net
InterestPaidNet
1679000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
512000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
638000 usd
lab Non Cash Right Of Use Assets And Lease Liabilities
NonCashRightOfUseAssetsAndLeaseLiabilities
211000 usd
lab Non Cash Right Of Use Assets And Lease Liabilities
NonCashRightOfUseAssetsAndLeaseLiabilities
0 usd
lab Asset Retirement Obligations Incurred But Not Yet Paid
AssetRetirementObligationsIncurredButNotYetPaid
740000 usd
lab Asset Retirement Obligations Incurred But Not Yet Paid
AssetRetirementObligationsIncurredButNotYetPaid
717000 usd
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, the current economic environment and on various other assumptions believed to be reasonable, which together form the basis for making judgments about the carrying values of assets and liabilities. These accounting matters included but were not limited to inventory and related reserves; the carrying value of goodwill and other long-lived assets; and the potential outcome of uncertain tax positions that have been recognized in the Company’s consolidated financial statements or tax returns. The Company also uses significant judgment in determining the fair value of financial instruments, including debt and equity instruments. Actual results could differ materially from these estimates and could have a material adverse effect on the Company’s condensed consolidated financial statements.</span></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassification</span></div><div style="margin-bottom:8pt;margin-top:8pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the condensed consolidated financial statements have been reclassified from their original presentation to conform to current year presentation.</span></div>
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
14366000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
14955000 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
75164000 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
75164000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
108506000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
109095000 shares
CY2023Q2 lab Number Of Additional Shares Issuable Under Make Whole Premium Maximum
NumberOfAdditionalSharesIssuableUnderMakeWholePremiumMaximum
4741374 shares
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27666000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18777000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52785000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45281000 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27666000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18777000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52785000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45281000 usd
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
15500000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
14600000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
6800000 usd
lab Contract With Customer Liability Increase From Cash Receipts
ContractWithCustomerLiabilityIncreaseFromCashReceipts
7700000 usd
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
9089000 usd
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
8453000 usd
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
4101000 usd
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1982000 usd
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
23625000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3000000 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3200000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
5900000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
6300000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
5835000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1407000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7242000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142304000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
81309000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
795000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1015000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
143099000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
82324000 usd
CY2023Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
16876000 usd
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
16866000 usd
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
447000 usd
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
945000 usd
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
12427000 usd
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
15245000 usd
CY2023Q2 us-gaap Inventory Gross
InventoryGross
29750000 usd
CY2022Q4 us-gaap Inventory Gross
InventoryGross
33056000 usd
CY2023Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7670000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
11583000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
22080000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
21473000 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
54271000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
53069000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
32038000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
29029000 usd
CY2023Q2 us-gaap Construction In Progress Gross
ConstructionInProgressGross
2289000 usd
CY2022Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
1612000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
24522000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
25652000 usd
CY2023Q2 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
3694000 usd
CY2022Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
1170000 usd
CY2023Q2 us-gaap Accrued Vacation Current
AccruedVacationCurrent
2873000 usd
CY2022Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
2795000 usd
CY2023Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1276000 usd
CY2022Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
1174000 usd
CY2023Q2 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
1922000 usd
CY2022Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
4014000 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9765000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9153000 usd
CY2020Q3 lab Research And Development Arrangement Contract To Perform For Others Maximum Contract Value
ResearchAndDevelopmentArrangementContractToPerformForOthersMaximumContractValue
34000000 usd
CY2020Q3 lab Research And Development Arrangement Contract To Perform For Others Capital Expenditures
ResearchAndDevelopmentArrangementContractToPerformForOthersCapitalExpenditures
22200000 usd
CY2023Q2 lab Research And Development Arrangement Contract To Perform For Others Depreciation Expense
ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense
900000 usd
CY2022Q2 lab Research And Development Arrangement Contract To Perform For Others Depreciation Expense
ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense
800000 usd
lab Research And Development Arrangement Contract To Perform For Others Depreciation Expense
ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense
1800000 usd
lab Research And Development Arrangement Contract To Perform For Others Depreciation Expense
ResearchAndDevelopmentArrangementContractToPerformForOthersDepreciationExpense
1700000 usd
CY2023Q2 lab Research And Development Arrangement Contract To Perform For Others Accumulated Depreciation Expenses
ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses
6000000 usd
CY2022Q4 lab Research And Development Arrangement Contract To Perform For Others Accumulated Depreciation Expenses
ResearchAndDevelopmentArrangementContractToPerformForOthersAccumulatedDepreciationExpenses
4200000 usd
CY2023Q2 lab Research And Development Arrangement Contract To Perform For Others Property And Equipment Net
ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet
16200000 usd
CY2022Q4 lab Research And Development Arrangement Contract To Perform For Others Property And Equipment Net
ResearchAndDevelopmentArrangementContractToPerformForOthersPropertyAndEquipmentNet
18000000 usd
CY2023Q2 us-gaap Long Term Debt
LongTermDebt
65245000 usd
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
64892000 usd
CY2023Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
138871000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
502000 usd
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
138369000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0 usd
CY2022Q4 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
20000000 usd
CY2023Q2 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
1208200 shares
CY2023Q2 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2400000 usd
CY2023Q2 us-gaap Treasury Stock Acquired Average Cost Per Share
TreasuryStockAcquiredAverageCostPerShare
1.97
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
2880993 shares
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
5400000 usd
CY2023Q2 us-gaap Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased
14600000 shares
CY2023Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10077000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7882000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.43
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y10M24D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1959000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.61
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
835000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.88
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9006000 shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.81
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P8Y9M18D
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
102000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
2826000 shares
CY2023Q2 lab Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
4.36
lab Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term One
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTermOne
P8Y2M12D
CY2023Q2 lab Share Based Compensation Arrangement By Share Based Payment Award Options Vested Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAggregateIntrinsicValue
22000 usd
lab Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingNumber
6180000 shares
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
2300000 usd
CY2022Q2 us-gaap Restructuring Charges
RestructuringCharges
300000 usd
us-gaap Restructuring Charges
RestructuringCharges
3400000 usd
us-gaap Restructuring Charges
RestructuringCharges
1700000 usd
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
4033000 usd
us-gaap Restructuring Charges
RestructuringCharges
3417000 usd
us-gaap Payments For Restructuring
PaymentsForRestructuring
5528000 usd
CY2023Q2 us-gaap Restructuring Reserve
RestructuringReserve
1922000 usd
CY2023Q2 lab Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageExercisePrice
3.56
lab Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Weighted Average Remaining Contractual Term1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestWeightedAverageRemainingContractualTerm1
P9Y1M6D
CY2023Q2 lab Share Based Compensation Arrangement By Share Based Payment Award Options Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue
80000 usd
CY2023Q2 us-gaap Share Price
SharePrice
1.93
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3114000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4663000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6262000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8705000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
300000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1600000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
600000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2200000 usd
CY2022Q3 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27666000 usd
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18777000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52785000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45281000 usd
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
2267000 usd
CY2022Q2 us-gaap Restructuring Charges
RestructuringCharges
300000 usd
us-gaap Restructuring Charges
RestructuringCharges
3417000 usd
us-gaap Restructuring Charges
RestructuringCharges
1690000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17449000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-38563000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-34042000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-66066000 usd
CY2023Q2 us-gaap Restructuring Charges
RestructuringCharges
2267000 usd
CY2022Q2 us-gaap Restructuring Charges
RestructuringCharges
300000 usd
us-gaap Restructuring Charges
RestructuringCharges
3417000 usd
us-gaap Restructuring Charges
RestructuringCharges
1690000 usd

Files In Submission

Name View Source Status
0001628280-23-028287-index-headers.html Edgar Link pending
0001628280-23-028287-index.html Edgar Link pending
0001628280-23-028287.txt Edgar Link pending
0001628280-23-028287-xbrl.zip Edgar Link pending
exhibit1010.htm Edgar Link pending
exhibit1011.htm Edgar Link pending
exhibit109.htm Edgar Link pending
exhibit31110q2q2023.htm Edgar Link pending
exhibit31210q2q2023.htm Edgar Link pending
exhibit32110q2q2023.htm Edgar Link pending
exhibit32210q2q2023.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_0a.jpg Edgar Link pending
lab-20230630.htm Edgar Link pending
lab-20230630.xsd Edgar Link pending
lab-20230630_g1.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
lab-20230630_cal.xml Edgar Link unprocessable
lab-20230630_def.xml Edgar Link unprocessable
lab-20230630_lab.xml Edgar Link unprocessable
lab-20230630_pre.xml Edgar Link unprocessable
lab-20230630_htm.xml Edgar Link completed
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending